Back to Results
Assessing Treatments for Patients with Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer
||Lung Cancer - Assessing Treatments for Patients with Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer
||Krishna Gunturu, MD
||Jennifer Caplain, RN
The primary purpose of the trial is to study the safety of combination therapy with chemoradiation, followed by consolidation, finally followed by the investigational drugs L-BLP25 and bevacizumab for patients with non-squamous, locally advanced Non Small Cell Lung Cancer (NSCLC).The other reasons for this study are to: study overall survival, toxicity, and progression-free survival for patients treated with L-BLP25 plus bevacizumab in addition to chemoradiation and consolidation therapy.
- Potential subjects must have newly diagnosed histologically confirmed non-squamous non small cell lung cancer
- Surgery to remove the cancer is not an option
- Potential subjects must have adequate liver, kidney, and heart function
- The potential subject cannot have brain/ spinal fluid metastases, or any other active cancers
- Potential subjects cannot have had previous chemotherapy or radiation therapy for lung cancer
- Potential subjects cannot have an active infection, have any autoimmune disease or have an immunodeficiency disease
Standard Chemoradiotherapy (radiation+chemotherapy drugs) during the week for 6.5 weeks, then 6 weeks of Standard Chemotherapy, then 24 months of study drugs L-BLP25 plus bevacizumab. During this time, there will be standard urine tests, blood tests, physical exams, and CT scans (3, then 1 every 9 weeks during study drug period).
Are you interested in learning more about this clinical trial?
Send us a message and we'll get back to you with more information.